相关实验视频
Updated: Jun 15, 2025
03:48
Restraint to Induce Stress in Mice and Rats
Published on: December 6, 2024
1.2K
在雄性大鼠的严重低血糖期间,诺拉上腺素会调节心脏阻塞
Emily H Nuibe1, Matthew E Chambers1, Candace M Reno-Bernstein1
1Division of Endocrinology, Metabolism, and Diabetes, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Physiological reports
|August 24, 2024
概括
严重的低血糖症可能是致命的,可能是由于心律不整. 作为压力荷尔蒙的一种,上腺素在大鼠严重低血糖期间显著增加了心脏阻塞和心肌梗塞标志物.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
背景情况:
- 严重的低血糖是1型糖尿病的常见且可能致命的并发症.
- 关联严重低血糖与死亡的确切机制,特别是心脏事件,仍然不完全理解.
- 交感神经系统,包括上腺素,与心律失常有关.
研究的目的:
- 为了研究一种假设,即上腺素是严重低血糖引起的致命心律失常的主要调解者.
- 阐明北上腺素在严重低血糖相关心脏功能障碍中的作用.
主要方法:
- 成年斯普拉格-道利大鼠接受了高胰岛素性严重低血糖 (3小时,10-15毫克/分升).
- 实验1: 脑内静脉注射 (ICV) 输注诺拉上腺素或人造脑脊液 (aCSF).
- 实验2:通过腹腔内储或对照剂的使用来阻断北上腺素的释放.
主要成果:
- 在严重低血糖症期间的ICV北上腺素输注显著增加了第三级心脏阻塞 (2.5倍) 和诱导的ST升高 (24%的发病率).
- 服用reserpine有效地降低了血和心脏的诺亚上腺素水平.
- 在接受保留素治疗的老鼠中,严重的低血糖症并没有导致二度或三度心脏阻塞或T波增加 (心肌梗塞标志物).
结论:
- 在严重低血糖症期间,上腺素在调节心律失常和心肌梗塞标志物方面发挥着至关重要的作用.
- 通过储减少北上腺素的释放,可以有效地预防这些不良心脏事件.
- 这些发现凸显了北上腺素在严重低血糖症中的前节律潜力,并提出了治疗点.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
546
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
546
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
01:16Antianginal Drugs: Nitrates and β-Blockers
550
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
550
01:17Antihypertensive Drugs: Action of β1 Blockers
339
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
339
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405